Cumberland Pharmaceuticals CPIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.94M-5.8% | $44.52M+7.9% | $41.28M-1.9% | $42.07M+2.4% | $41.08M+8.5% | ||
| $7.18M+7.6% | $6.67M+4.1% | $6.4M-5.0% | $6.74M+4.7% | $6.44M-2.3% | ||
| $34.76M-8.2% | $37.85M+8.5% | $34.88M-1.3% | $35.34M+2.0% | $34.65M+10.8% | ||
| 82.9%-2.1pp | 85%+0.5pp | 84.5%+0.5pp | 84%-0.3pp | 84.3%+1.7pp | ||
| $5.73M+2.9% | $5.57M+4.8% | $5.31M-1.0% | $5.36M+8.3% | $4.95M+2.8% | ||
| $19.93M+4.4% | $19.1M+11.6% | $17.11M+0.2% | $17.08M-0.1% | $17.1M+0.5% | ||
| $12.04M+0.8% | $11.95M+6.3% | $11.24M-0.9% | $11.34M+1.0% | $11.22M+0.9% | ||
| $4.28M+6.0% | $4.03M-10.0% | $4.48M-1.5% | $4.55M-2.0% | $4.64M-2.2% | ||
| $49.15M+3.9% | $47.31M+6.2% | $44.54M-1.2% | $45.06M+1.6% | $44.35M+0.1% | ||
| -$7.21M-158% | -$2.79M+14.4% | -$3.26M-9.1% | -$2.99M+8.5% | -$3.27M+49.1% | ||
| -17.2%-10.9pp | -6.3%+1.6pp | -7.9%-0.8pp | -7.1%+0.9pp | -8%+9.0pp | ||
| $418.03K-15.7% | $495.99K-18.2% | $606.31K-4.4% | $633.98K-2.6% | $650.78K+7.5% | ||
| $429.07K-10.0% | $476.75K-3.0% | $491.45K+14.5% | $429.06K+18.1% | $363.41K+8.7% | ||
| —— | —— | —— | —— | $0— | ||
| -$7.2M-156% | -$2.81M+16.8% | -$3.38M-14.1% | -$2.96M+10.9% | -$3.32M+48.6% | ||
| $38.46K-4.5% | $40.26K+201% | -$39.99K-16.9% | -$34.21K-20.3% | -$28.44K-25.5% | ||
| -$7.38M-160% | -$2.84M+14.8% | -$3.33M-13.5% | -$2.93M+10.5% | -$3.28M+49.4% | ||
| -17.6%-11.2pp | -6.4%+1.7pp | -8.1%-1.1pp | -7%+1.0pp | -8%+9.1pp | ||
| -$0.49-158% | -$0.19+20.8% | -$0.24-9.1% | -$0.22+12.0% | -$0.25+46.8% | ||
| -$0.49-158% | -$0.19+20.8% | -$0.24-9.1% | -$0.22+12.0% | -$0.25+46.8% | ||
| 59.7M-0.5% | 60M+1.3% | 59.2M+1.6% | 58.3M+1.5% | 57.5M+2.1% | ||
| 59.7M0.0% | 59.7M+1.3% | 58.9M+1.6% | 58M+1.5% | 57.2M+1.5% | ||
| $4.28M+6.0% | $4.03M-10.0% | $4.48M-1.5% | $4.55M-2.0% | $4.64M-2.2% | ||
| $41.94M-5.8% | $44.52M+7.9% | $41.28M-1.9% | $42.07M+2.4% | $41.08M+8.5% | ||
| -$7.21M-158% | -$2.79M+14.4% | -$3.26M-9.1% | -$2.99M+8.5% | -$3.27M+49.1% | ||
| -$2.82M-309% | $1.35M+1.2% | $1.34M-20.7% | $1.69M+11.5% | $1.51M+199% | ||
| -$2.82M-309% | $1.35M+1.2% | $1.34M-20.7% | $1.69M+11.5% | $1.51M+199% | ||
| -6.7%-9.8pp | 3%-0.2pp | 3.2%-0.8pp | 4%+0.3pp | 3.7%+7.7pp | ||
| -$7.21M-158% | -$2.79M+14.4% | -$3.26M-9.1% | -$2.99M+8.5% | -$3.27M+49.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cumberland Pharmaceuticals's revenue?
- Cumberland Pharmaceuticals (CPIX) generated $41.9M in revenue over the trailing twelve months, up 2.1% year over year.
- Is Cumberland Pharmaceuticals profitable?
- Cumberland Pharmaceuticals is not currently profitable: it reported a net loss of $7.4M over the trailing twelve months, a -17.6% net margin.
- What are Cumberland Pharmaceuticals's profit margins?
- Gross margin is 82.9% and operating margin is -17.2%, with a -17.6% net margin.
- What is Cumberland Pharmaceuticals's earnings per share?
- Cumberland Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.49.
- Where does Cumberland Pharmaceuticals's income statement data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
